BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Randolph JT, Voight EA, Greszler SN, Uno BE, Newton JN, Gleason KM, Stolarik D, Van Handel C, Bow DAJ, DeGoey DA. Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530). J Med Chem 2020;63:11034-44. [PMID: 32881503 DOI: 10.1021/acs.jmedchem.0c00956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Voight EA, Greszler SN, Kym PR. Fueling the Pipeline via Innovations in Organic Synthesis. ACS Med Chem Lett 2021;12:1365-73. [PMID: 34531945 DOI: 10.1021/acsmedchemlett.1c00351] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Groaz E, De Clercq E, Herdewijn P. Anno 2021: Which antivirals for the coming decade? Annu Rep Med Chem 2021;57:49-107. [PMID: 34744210 DOI: 10.1016/bs.armc.2021.09.004] [Reference Citation Analysis]
3 Kim H, Kim C, Jo A, Kim J. Studies on Preformulation and Formulation of JIN-001 Liquisolid Tablet with Enhanced Solubility. Pharmaceuticals 2022;15:412. [DOI: 10.3390/ph15040412] [Reference Citation Analysis]
4 Voight EA, Greszler SN, Hartung J, Ji J, Klix RC, Randolph JT, Shelat BH, Waters JE, DeGoey DA. Desymmetrization of pibrentasvir for efficient prodrug synthesis. Chem Sci 2021;12:10076-82. [PMID: 34349971 DOI: 10.1039/d1sc02396a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]